

Dedication

**I dedicate this research
to the soul of my father
who tells me the
meaning of life
To my Mather
To every women
suffering and seeking for
a care**

Acknowledgement

Firstly and endly thanks go to ***god" ALLAH"*** for helping me to complete this research.

I am greatly indebted to my supervisor ***Dr. Ammed Abd Albadie Mohmed,***

Department of histopathology in Ribat hospital, associate Professor in faculty of medicine in Ribat university for his encouragement ,guidance, valuable criticisms and patience throughout this research.

Deep thanks are extended to ***DR. Shawgi Osman*** director of directorate of labrotary For his permission to collect the specimen, and his guidance. Also deep thanks to ***MR ABo AL gasim*** for his help in analysis program.

I wish to express my thanks to the ***staff members of department of histopathology in Rebat hospital*** to there help in archived specimen.

I wish to extent my thanks to ***Mr .HussienSharief Siddig*** for his invaluable comment. Thanks to ***Miss Amal Abd Al hamied*** for her support .Thanks to my brother ***MR Mohamed al KHatim , MR Mohamed al Mustafa,MR Mohamed Al Adnani Ahmed Abd Al All*** for their support and encouragement.

Tables of Contents

Contents	Page No.
Dedication	I
Acknowledgement	II
List of Contents	III
List of Tables	VI
List of Figures	VII
List of photo	VIII
Abstract (English)	IX
Abstract (Arabic)	XI
<i>CHAPTER ONE</i>	
Introduction and literature review	
1.1. Introduction	1
1.2. History breast cancer	1
1.3. Histology of breast	2
1.4. Benign breast condition	3
1.5. Most common symptoms of breast cancer	3
1.6. Cause of breast cancer	3
1.7. Type of breast cancer	4
1.8. Pathology of breast cancer	5
1.9. Diagnosis	6
2.Literature review	8
2.1. Factors affecting breast cancer	8
2.2. Estrogen and progesterone receptors in breast cancer	9
2.2.1. Positive VS. Negative Estrogen status	9
2.2.2. Positive VS. negative progesterone status	9
2.3. Epidemiological	14
2.4. The incidence of breast cancer	14
2.5. Treatment of breast cancer	15
2.5.1. Response to Hormonal therapy	16
2.5.2. Tamoxifen and cancer	16
2.6. Immuno histochemistry	17

2.6.1. Advantage of immunohistochemistry (IHC)	18
2.6.2. Antigen retrieval techniques	18
2.6.3. strategies used in immunohistochemistry	19
2.6.3.1. Method used in immune histochemistry	20
2.6.4. Immuno sensitivity charts	21
2.6.5.1. Avidness biotin complex (ABC) method	21
2.6.5.2. Advantages of the Biotin Avidin system	22
2.6.5.3. Disadvantage of Avidin biotin technique	23
2.7. False positive result (spurious staining)	23
2.7.1. Falls negative result	24
<i>Chapter Two</i>	
Rational and objective	26
<i>Chapter Three: Material and Method</i>	
3.1. Study design	27
3.2. study area	27
3.3. Study population	27
3.4. Sample collection	27
3.5. Sample preparation	28
3.6. Method	28
3.7. Result Assessment	30
3.8. Statistical analysis	30
3.9. Ethical consideration	30
<i>Chapter Four: Results</i>	
Results	31-47
<i>Chapter Five</i>	
Discussion	48
Conclusion and Recommendation	52

References	53
------------	----

List of Table

Table	No.
Table (1): Describe the distribution of study group according the type of cancer (ductal, non- ductal carcinoma)	31
Table (2): Correlates between ER/expression of estrogen receptors) and type of caner (ductal or non – ductal)	32
Table (3): Correlates between the expression of PR receptor (progesterone receptor) and type of breast cancer (ductal or non ductal carcinoma)	33
Table (4): Expression of ER receptor among the study group	34
Table (5): Expression of PR receptor among the study group	35
Table (6): pattern of ER and PR expression among the study group	36

List of Figures

Figure	No.
Figure (1): Distribution of breast cancer patients according to their age in the study group	37
Figure (2): Relation between type of breast cancer and age	38
Figure (3): Expression of ER receptor (ER positivity) in patients having ductal carcinoma compared to other types of carcinoma (non ductal)	39
Figure (4): Describes the pattern of PR receptor expression among patients having ductal carcinoma and those having non-ductal carcinoma	40
Figure (5): Incidence of ER/PR subtype among study group	41

List of Photo

Photo	No.
Photo (1): Show section of ductal carcinoma of breast, ER receptor was positive expression by (immunohistochemistry) (avidin biotin, x40)	42
Photo (2): Show section of ductal carcinoma of breast, PR receptor was positive expression by (immunohistochemistry) (avidin biotin, x40)	43

Abstract

This is a descriptive hospital base study aimed to determine the expression of estrogen and progesterone receptors in breast cancer females in Khartoum state.

The study was carried out in Khartoum state during the period between Jan 2008 Jan 2009.

Fifty archived specimens of embedded paraffin wax block were collected from histopathology lab of Ribat hospital and directorate of labrotaries and the essential data was collected from patient form.

The disease was distributed in tree group of age women less than 30 Years were (4%) ,women between 30-50years were (43%) and women over 50 years were (53%), Ductal carcinoma is the most distributed type of breast cancer among the study group (74%).

After applying imunohistochemistry technique using avidin biotin method the results showed that out of (37) women having ductal carcinoma with ER positive are 10(20%) whereas carcinoma with ER negative is 27(54%). While out of (13) with non- ductal carcinoma with the expression of ER positive are 12 (24%) and those with non- ductal carcinoma and ER negative are 1 (2%).with significant correlation between types of breast cancer and expression of ER receptors P. value <0.01.

Females having ductal carcinoma and positive expression of PR receptor were 10 (20%), ductal carcinoma and negative expression of PR receptor were 27(54%), non-ductal carcinoma and positive expression of PR receptor were 3(6%) and non-ductal carcinomas negative expression were

PR receptor were 10(20%) With significant correlation between type of breast cancer and expression of PR receptor, P. value <0.01 .

The incidence of ER/PR subtypes among the study group showed (ER+/PR+)were 24% those having(ER+/PR-)were 12%. Those having (ER-/PR+) were 4%,those having (ER-/PR-)were high incidence shows 60%.

The study showed that there is no significant correlation between age and type of cancer also between age and expression of ER and PR receptors.

The study recommended more effort for breast cancer were needed, also large sample size to determine the expression of ER and PR receptors among breast cancer.

Applying the immunohistochemistry investigation for (ER-/PR-) negative receptors as routine test to help diagnosis , treatment by hormonal therapy and prognosis.

خلاصة الأطروحة

أجريت هذه الدراسة الوصفية المستشفوية المتراجعة بهدف تحديد تعبر مستقبلات الاستروجين والبروجسترون في سرطان الثدي لدى النساء في ولاية الخرطوم.

الدراسة أجريت في ولاية الخرطوم في الفترة ما بين 2008-2009م، خمسون عينة أرشيفية من القوالب المغمورة بشمع البارفين جمعت من معمل الأنسجة المريضة بمستشفى الرباط الجامعي ومعمل الأنسجة المريضة بإدارة المعامل ولاية الخرطوم وأخذت المعلومات الخاصة بالمريض من فايلات الأرشيف.

تم توزيع النساء في هذه الدراسة اعتماداً على الأعمار إلى ثلاثة فئات عمرية النساء أقل عمراً من ثلاثين ويمثلن (4%) والنساء ما بين 30-50 ويمثلن (43%) ونساء أكبر من خمسين عاماً ويمثلن (53%) ولقد وجد أن سرطان الثدي القنوى هو الأكثر شيوعاً بين النساء بنسبة (74%).

عند تطبيق التشخيص النسيجي المناعي بتقنية (استربتو افدين بيوتين) المعلمة بالملون (Dab) تم استخلاص النتائج الآتية: تعبر مستقبلات الأستروجين الإيجابي في عينات سرطان الثدي القنوى يمثل 10 (20%) أما الأستروجين السلبى يمثل 27 (54%) ، أما في سرطان الثدي الغير قنوى فكان تعبر مستقبلات الأستروجين الإيجابي 12 (24%) والسلبى يمثل 1 (2%) ولقد وجدت علاقة احصائية بين نوع سرطان الثدي وتعبر مستقبلات الاستروجين لدى ($P < 0.01$).

النساء اللائى اظهرت نتائج تعبر ايجابى لمستقبلات البروجسترون في سرطان الثدي القنوى يمثلن 10 (20%) أما السلبيات لمستقبلات البروجسترون يمثلن 27 (54%) أما في سرطان الثدي الغير قنوى كان تعبر مستقبلات البروجسترون الإيجابى يمثل 3 (6%) ، أما السلبى يمثل 10 (20%).

توجد علاقة ذات دلالة احصائية بين نوع السرطان وتعبر مستقبلات البروجسترون ($P < 0.01$).

كانت معدلات حدوث النمط (الاستروجين/ البروجسترون) (ER/PR) بين مجموعة الدراسة كالآتى:

(+ER+/ PR) يمثل (24%) ، أما (-ER+/PR) يمثل (12%) بينما (+ER-/PR) يمثل (4%) وكان أكثر الأنماط حدوثاً هو (-ER-/PR) يمثل (60%) .

وقد أظهرت الدراسة أنه لا توجد علاقة بين العمر ونوع السرطان الثدي بل توجد علاقة ذات دلالة احصائية بين العمر وتعبير مستقبلات الاستروجين والبروجيستيرون وذلك يبدو واضحاً في الفئة العمرية الأكثر من خمسون عاماً.

أوصت الدراسة بضرورة وجود برنامج مسح لسرطان الثدي بالسودان واستخدام عدد أكبر من العينات لتحديد تعبير مستقبلات الاستروجين والبروجيستيرون.

تطبيق التشخيص المناعي النسيجي لمستقبلات الاستروجين والبروجيستيرون لتحديد نوع العلاج الهرموني والمتابعة.

Chapter one

Introduction and Literature review

Chapter TWO

Rationale and Objective

Chapter Three

Material and Method

Chapter Four

Results

Chapter Five

Discussion